The FDA announced that drug manufacturers will now be required to include information about naloxone in prescribing information for opioids and medications to treat opioid use disorders.
FDA Commissioner Stephen M. Hahn, MD, said in a press release that the action “can help further raise awareness about this potentially life-saving treatment for individuals who may be at greater risk of an overdose and those in the community most likely to observe an overdose.”
In a Drug Safety Communication, the agency said labeling should recommend that health care professionals discuss the
Uncategorized